We recently compiled a list of 11 Best Future Stocks to Buy Now. CG Oncology, Inc. stands sixth on our list.
CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company developing bladder-sparing immunotherapies, with a primary focus on cretostimogene grenadenorepvec, a targeted oncolytic virus therapy for bladder cancer. Their lead program targets high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), an area with limited options beyond invasive surgery.
Recent data from the Phase 3 BOND-003 trial, presented in June 2025, revealed a 75.5% complete response rate, with 42.3% of patients maintaining that response at 24 months. Impressively, 97.3% remained free of progression to muscle-invasive disease, and 91.6% avoided cystectomy. The therapy was also well-tolerated, with no grade 3 or higher treatment-related adverse events reported.
Cretostimogene stands out as a potential new standard for NMIBC, offering durable cancer control without surgery and preserving patients’ quality of life. Its promising results have sparked interest in combining it with other therapies like pembrolizumab, further expanding its therapeutic potential.
A healthcare specialist in the laboratory testing an Oncology-related product.
CG Oncology, Inc. (NASDAQ:CGON) continues to expand its clinical footprint with trials targeting both BCG-naïve and previously treated patients. A Biologics License Application (BLA) is expected soon, supported by strong Phase 2 combination data published in Nature Medicine. The business is also offering expanded access programs, broadening patient reach before full regulatory approval.
While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
